Book a Meeting

Anti-PD-1 & LAG-3 Antibody, ADCC Enchanced (BioBet-CB-024LX) (CAT#: BioBet-CB-024LX) Datasheet

Target
PD-1 & LAG-3
Isotype
IgG4
Description
Anti-PD-1 & LAG-3 Antibody, ADCC Enchanced (BioBet-CB-024LX) is a glycosylation-modified anti-PD-1 & LAG-3 therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced PD-1 & LAG-3 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
PD-1;
LAG-3;
Full Name
Programmed cell death protein 1;
Lymphocyte activation gene 3 protein;
Background
Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers. PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.
Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation and growth. T cells are a type of white blood cell that are part of the immune system. Activation of cytotoxic T cells by antigens enables them to kill unhealthy or foreign cells.
Alternative Names
PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; Hsle1;
Lymphocyte activation gene 3 protein; LAG-3; CD antigen CD223;
Gene ID
5133;
3902
UniProt ID
Q15116;
Q61790;
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG4
Antibody Clone
BioBet-CB-024LX
Host
Human
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human PD-1 & LAG-3 (MGD013) Antibody is derived from clone MGD013, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the PD-1 & LAG-3, and it is intended for the research of Gastric cancer/gastro-esophageal junction adenocarcinoma.
Antibody Indication
Gastric cancer/gastro-esophageal junction adenocarcinoma

Gastric cancer/gastro-esophageal junction adenocarcinoma

Related Products

Anti-PD-1 & LAG-3 Antibody, ADCC Enchanced (BioBet-CB-041LX) (CAT#: BioBet-CB-041LX)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.